Article
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Cancer - 1 Jan 2020
Zang Hongjing, Qian Guoqing, Zong Dan, Fan Songqing, Owonikoko Taofeek K, Ramalingam Suresh S, Sun Shi-Yong
Abstract excerpt
BACKGROUND: The major clinical obstacle that limits the long-term benefits of treatment with osimertinib (AZD9291) in patients with epidermal growth factor receptor-mutant non-small cell lung cancer is the development of acquired resistance. Therefore, effective strategies that can overcome acquired resistance to osimertinib are urgently needed. The authors' current efforts in this direction have identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.